Galapagos reports record revenues and net profit for 2009, foresees sustained profitability • Total revenues of €106 M (+34%) • Group net profit of €3 M • R&D revenues of €63.8 M (+76%), driven by alliances • BioFocus recurrent segment profit of €7.9 M (+174%) • Cash position of €47.4 M at year-end • Four programs moved into clinical development • 2010 guidance: profitability and positive cash-flow, revenues more than €135 million
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.